Grand Pharmaceutical's FAP-Targeted Nuclear Drug GPN01530-2 Gets FDA Fast Track Designation

Grand Pharmaceutical disclosed in an announcement on August 9 that its FAP-targeted innovative nuclear drug GPN01530-2 has been granted Fast Track designation by the US Food and Drug Administration (FDA). The drug had previously received FDA approval to conduct Phase I/II clinical studies for the diagnosis of solid tumors.